Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience

Siddhartha Ganguly; Jaswinder Singh; Clint L. Divine; Delva Deauna-Limayo; David C. Bodensteiner; Jan L. Lewis; Kathy Curran; Barry S. Skikne

doi:10.1016/j.leukres.2006.12.021

Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience

Siddhartha Ganguly, Jaswinder Singh, Clint L. Divine, Delva Deauna-Limayo, David C. Bodensteiner, Jan L. Lewis, Kathy Curran, Barry S. Skikne

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

In an attempt to examine whether autologous SCT provides long-term disease control in patients with intermediate and high-risk AML where a suitable donor is not available, we analyzed the outcomes of autologous SCT in patients with intermediate and high-risk AML from 1986 to 2005. No relapses occurred after 2.2 years. The overall survival curve appears to have developed a plateau after 2.2 years. In conclusion, autologous SCT in patients with AML in whom an allogeneic transplantation is not feasible appears to be a safe alternative and a plateau in the survival curve indicates cure in a small proportion of patients.

Original language	English (US)
Pages (from-to)	1253-1257
Number of pages	5
Journal	Leukemia Research
Volume	31
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2006.12.021
State	Published - Sep 2007

Keywords

Acute myeloid leukemia
Bone marrow transplantation
Stem cell transplantation

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2006.12.021

Cite this

Ganguly, S., Singh, J., Divine, C. L., Deauna-Limayo, D., Bodensteiner, D. C., Lewis, J. L., Curran, K., & Skikne, B. S. (2007). Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience. Leukemia Research, 31(9), 1253-1257. https://doi.org/10.1016/j.leukres.2006.12.021

Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience. / Ganguly, Siddhartha; Singh, Jaswinder; Divine, Clint L.; Deauna-Limayo, Delva; Bodensteiner, David C.; Lewis, Jan L.; Curran, Kathy; Skikne, Barry S.

In: Leukemia Research, Vol. 31, No. 9, 09.2007, p. 1253-1257.

Research output: Contribution to journal › Article › peer-review

Ganguly, S, Singh, J, Divine, CL, Deauna-Limayo, D, Bodensteiner, DC, Lewis, JL, Curran, K & Skikne, BS 2007, 'Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience', Leukemia Research, vol. 31, no. 9, pp. 1253-1257. https://doi.org/10.1016/j.leukres.2006.12.021

Ganguly, Siddhartha ; Singh, Jaswinder ; Divine, Clint L. ; Deauna-Limayo, Delva ; Bodensteiner, David C. ; Lewis, Jan L. ; Curran, Kathy ; Skikne, Barry S. / Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience. In: Leukemia Research. 2007 ; Vol. 31, No. 9. pp. 1253-1257.

@article{b3bf47c58254464abe6972d5bc2c66f2,

title = "Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience",

abstract = "In an attempt to examine whether autologous SCT provides long-term disease control in patients with intermediate and high-risk AML where a suitable donor is not available, we analyzed the outcomes of autologous SCT in patients with intermediate and high-risk AML from 1986 to 2005. No relapses occurred after 2.2 years. The overall survival curve appears to have developed a plateau after 2.2 years. In conclusion, autologous SCT in patients with AML in whom an allogeneic transplantation is not feasible appears to be a safe alternative and a plateau in the survival curve indicates cure in a small proportion of patients.",

keywords = "Acute myeloid leukemia, Bone marrow transplantation, Stem cell transplantation",

author = "Siddhartha Ganguly and Jaswinder Singh and Divine, {Clint L.} and Delva Deauna-Limayo and Bodensteiner, {David C.} and Lewis, {Jan L.} and Kathy Curran and Skikne, {Barry S.}",

year = "2007",

month = sep,

doi = "10.1016/j.leukres.2006.12.021",

language = "English (US)",

volume = "31",

pages = "1253--1257",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience

AU - Ganguly, Siddhartha

AU - Singh, Jaswinder

AU - Divine, Clint L.

AU - Deauna-Limayo, Delva

AU - Bodensteiner, David C.

AU - Lewis, Jan L.

AU - Curran, Kathy

AU - Skikne, Barry S.

PY - 2007/9

Y1 - 2007/9

N2 - In an attempt to examine whether autologous SCT provides long-term disease control in patients with intermediate and high-risk AML where a suitable donor is not available, we analyzed the outcomes of autologous SCT in patients with intermediate and high-risk AML from 1986 to 2005. No relapses occurred after 2.2 years. The overall survival curve appears to have developed a plateau after 2.2 years. In conclusion, autologous SCT in patients with AML in whom an allogeneic transplantation is not feasible appears to be a safe alternative and a plateau in the survival curve indicates cure in a small proportion of patients.

AB - In an attempt to examine whether autologous SCT provides long-term disease control in patients with intermediate and high-risk AML where a suitable donor is not available, we analyzed the outcomes of autologous SCT in patients with intermediate and high-risk AML from 1986 to 2005. No relapses occurred after 2.2 years. The overall survival curve appears to have developed a plateau after 2.2 years. In conclusion, autologous SCT in patients with AML in whom an allogeneic transplantation is not feasible appears to be a safe alternative and a plateau in the survival curve indicates cure in a small proportion of patients.

KW - Acute myeloid leukemia

KW - Bone marrow transplantation

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=34249882484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249882484&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.12.021

DO - 10.1016/j.leukres.2006.12.021

M3 - Article

C2 - 17320953

AN - SCOPUS:34249882484

VL - 31

SP - 1253

EP - 1257

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -

Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this